Assessing Circulating Tumor Cell as a Biomarker for Prostate Cancer Detection in Patients With Gray Zone PSA Level

CellMaxLife500 enrolled

Overview

Prostate cancer screening with PSA is plagued by high rate of unnecessary prostate biopsies, especially in the "gray zone" (4.00ng/ml e 10.99ng/ml). We introduce a new circulating-tumor-cell (CTC) biomarker for detection of prostate cancer in patients in the PSA "gray zone" level, with the clinically verified potential to substantially decrease the number of unnecessary prostate biopsies.

Study Type

OBSERVATIONAL

Enrollment

500

Conditions

Prostate Cancer

Eligibility

Sex: MALEMin age: 20 YearsMax age: 99 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Subjects are willing to sign the informed consent and agree to comply with the study procedures. * Age from 20 to 99 years old * Subjects with a PSA 4.00- 10.99 ng/ml and will receive biopsy within 3 months Exclusion Criteria: * Age \< 20 years * Refuse to sign the informed consent form * Received regional anesthesia and general anesthesia within one month * Previous cancer history * Autoimmune diseases * Chronic inflammatory diseases * Diagnosed with colorectal polyps or adenomas * Acute inflammatory or infectious diseases in three months * Other diseases decided by PI

Locations (1)

Linkou Chang Gung Memorial Hospital

Taoyuan, Taiwan

RECRUITING

Outcomes

Primary Outcomes

Circulating tumor cells detection

Using a circulating-tumor-cell (CTC) test to detect prostate cancer in patients in the PSA "gray zone" level

Time frame: Prior to prostate biopsy

Central Contacts

Joy Chang

CONTACT

+886-2-26558455 joy@cellmaxlife.com

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.